{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:14:38Z","timestamp":1787786078400,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.acuroe.2025.501717","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T17:15:56Z","timestamp":1739380556000},"page":"501717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review"],"prefix":"10.1016","volume":"49","author":[{"given":"A.A.","family":"Grosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cadenar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lipparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Di Maida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mancon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yuen-Chun Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.acuroe.2025.501717_bib0005","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol."},{"issue":"3","key":"10.1016\/j.acuroe.2025.501717_bib0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol."},{"key":"10.1016\/j.acuroe.2025.501717_bib0015","article-title":"EAU guidelines","year":"2023","journal-title":"Presented at the EAU Annual Congress Milan 2023"},{"issue":"17","key":"10.1016\/j.acuroe.2025.501717_bib0020","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u2018unfit\u2019 for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2025.501717_bib0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4111\/icu.20200132","article-title":"Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer","volume":"61","author":"McFerrin","year":"2020","journal-title":"Investig Clin Urol."},{"key":"10.1016\/j.acuroe.2025.501717_bib0030","unstructured":"FDA. FDA approves nivolumab for adjuvant treatment of urothelial carcinoma. Available from: https:\/\/www.fda.gov\/drugs\/resources-informationapproved-drugs\/fda-approves-nivolumab-adjuvant-treatmenturothelial-carcinoma."},{"key":"10.1016\/j.acuroe.2025.501717_bib0035","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/iju.14082","article-title":"Predictive biomarkers for drug response in bladder cancer","volume":"26","author":"Yoshida","year":"2019","journal-title":"Int J Urol."},{"key":"10.1016\/j.acuroe.2025.501717_bib0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/app13010275","article-title":"The role of miRNA in the management of localized and advanced renal masses, a narrative review of the literature","volume":"13","author":"Napolitano","year":"2023","journal-title":"Appl Sci."},{"key":"10.1016\/j.acuroe.2025.501717_bib0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.23736\/S2724-6051.24.05821-X","article-title":"Complete response of metastatic RCC with caval vein thrombus following treatment with pembrolizumab and axitinib: is it possible to extend the indications for systemic therapy?","volume":"76","author":"Grosso","year":"2024","journal-title":"Minerva Urol Nephrol."},{"key":"10.1016\/j.acuroe.2025.501717_bib0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2567.2005.02130.x","article-title":"The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells","volume":"115","author":"Choi","year":"2005","journal-title":"Immunology."},{"key":"10.1016\/j.acuroe.2025.501717_bib0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1749-6632.2000.tb06608.x","article-title":"The origin and mechanism of circulating DNA","volume":"906","author":"Stroun","year":"2000","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.acuroe.2025.501717_bib0060","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.acuroe.2025.501717_bib0065","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med."},{"issue":"302","key":"10.1016\/j.acuroe.2025.501717_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med."},{"issue":"7655","key":"10.1016\/j.acuroe.2025.501717_bib0075","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature."},{"issue":"Mar 22","key":"10.1016\/j.acuroe.2025.501717_bib0080","article-title":"Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy","author":"Ben-David","year":"2024","journal-title":"Eur Urol Oncol."},{"key":"10.1016\/j.acuroe.2025.501717_bib0085","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","author":"Sfakianos","year":"2024","journal-title":"Eur Urol Oncol."},{"issue":"1","key":"10.1016\/j.acuroe.2025.501717_bib0090","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci Rep."},{"issue":"4","key":"10.1016\/j.acuroe.2025.501717_bib0095","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Birkenkamp-Demtr\u00f6der","year":"2018","journal-title":"Eur Urol."},{"issue":"18","key":"10.1016\/j.acuroe.2025.501717_bib0100","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol."},{"issue":"19","key":"10.1016\/j.acuroe.2025.501717_bib0105","doi-asserted-by":"crossref","first-page":"11732","DOI":"10.3390\/ijms231911732","article-title":"Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer","volume":"23","author":"Carrasco","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"2","key":"10.1016\/j.acuroe.2025.501717_bib0110","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol."},{"issue":"7867","key":"10.1016\/j.acuroe.2025.501717_bib0115","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature."},{"issue":"8","key":"10.1016\/j.acuroe.2025.501717_bib0120","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.acuroe.2025.501717_bib0125","doi-asserted-by":"crossref","first-page":"642","DOI":"10.23736\/S2724-6051.22.04959-X","article-title":"Analysis of molecular and clinical markers of resistance to bacillus of Calmette-Gu\u00e9rin immunotherapy in patients with urothelial non-muscle invasive bladder cancer","volume":"74","author":"DI Maida","year":"2022","journal-title":"Minerva Urol Nephrol."},{"key":"10.1016\/j.acuroe.2025.501717_bib0130","doi-asserted-by":"crossref","DOI":"10.1177\/1756287221995683","article-title":"Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer","volume":"13","author":"Di Maida","year":"2021","journal-title":"Ther Adv Urol."},{"key":"10.1016\/j.acuroe.2025.501717_bib0135","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/2090598X.2020.1814974","article-title":"Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer","volume":"19","author":"Mari","year":"2020","journal-title":"Arab J Urol."},{"key":"10.1016\/j.acuroe.2025.501717_bib0140","doi-asserted-by":"crossref","first-page":"9899","DOI":"10.3390\/ijms25189899","article-title":"Protein-based predictive biomarkers to personalize neoadjuvant therapy for bladder cancer-a systematic review of the current status","volume":"25","author":"Bedore","year":"2024","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.acuroe.2025.501717_bib0145","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Future Oncol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625000071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625000071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:22:52Z","timestamp":1750677772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578625000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2173578625000071"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501717","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA in muscle-invasive bladder cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2025.501717","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEU.","name":"copyright","label":"Copyright"}],"article-number":"501717"}}